22 Recruiting Leukemia Phase 1 Clinical Trials
Active phase 1 studies for leukemia enrolling across the USA. Verify eligibility and contact site coordinators.
All Leukemia studiesPhase 1 Studies for Leukemia
AZD6738 for Patients With Progressive MDS or CMML
📍 BIDMC — Boston, Massachusetts
View Study & Checklist ➔Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
📍 University of Chicago — Chicago, Illinois
View Study & Checklist ➔A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
📍 Children's Hospital Los Angeles — Los Angeles, California
View Study & Checklist ➔Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma
📍 Children's Hospital Los Angeles — Los Angeles, California
View Study & Checklist ➔Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
📍 Children's Hospital Los Angeles — Los Angeles, California
View Study & Checklist ➔Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
📍 BMT Program at Northside Hospital — Atlanta, Georgia
View Study & Checklist ➔Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
📍 Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
View Study & Checklist ➔Mosunetuzumab for CLL MRD Clearance
📍 Brigham & Women's Hospital — Boston, Massachusetts
View Study & Checklist ➔CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
📍 University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
View Study & Checklist ➔Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
📍 Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
View Study & Checklist ➔A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
📍 The University of Arizona — Tucson, Arizona
View Study & Checklist ➔A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
📍 St. Jude Children's Research Hospital — Memphis, Tennessee
View Study & Checklist ➔Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
📍 University of Colorado Hospital — Aurora, Colorado
View Study & Checklist ➔Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
📍 Stanford University — Palo Alto, California
View Study & Checklist ➔Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
📍 Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
View Study & Checklist ➔A Study of Revumenib and Mezigdomide in People With Leukemia
📍 City of Hope Cancer Center (Data collection only) — Duarte, California
View Study & Checklist ➔Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔